Oil prices hold sharp losses with focus on secondary India tariffs
Genprex , Inc., a pharmaceutical company based in Austin, Texas, has received notifications from The Nasdaq Stock Market indicating non-compliance with certain listing requirements. Currently trading at $0.51, down over 40% year-to-date according to InvestingPro data, the stock faces significant challenges.
On February 7, 2025, Nasdaq informed Genprex that its stock had failed to maintain the minimum bid price of $1.00 over the past 30 consecutive business days, violating the Nasdaq Capital Market’s listing rules.
Despite the warning, Genprex’s common stock will continue to be listed and traded on The Nasdaq Capital Market without immediate consequence. The company has until August 6, 2025, to meet the minimum bid price requirement. The stock, which has fallen from its 52-week high of $5.41 to current levels, faces an uphill battle.
If, during the 180-day grace period, Genprex’s stock closes at or above $1.00 for at least 10 consecutive business days, Nasdaq may confirm the company’s compliance, effectively resolving the issue. However, if compliance is not achieved by the deadline, Genprex may receive an additional 180 days to address the deficiency, potentially through a reverse stock split.
Additionally, Genprex had previously been notified of non-compliance with the minimum stockholders’ equity requirement. A plan to regain compliance was submitted on December 30, 2024, and on February 11, 2025, Nasdaq granted the company an extension. To satisfy the terms of this extension, Genprex must report $2.5 million in stockholders’ equity in its upcoming quarterly report due by May 15, 2025, and declare its ability to maintain compliance.
Failure to meet these conditions could lead to delisting, although Genprex would have the right to appeal any such decision. The company has stated its intention to monitor its stock price closely and consider potential solutions to regain compliance, but there is no certainty that it will succeed in doing so for either the minimum bid price or the stockholders’ equity requirements.
This news comes as a challenge to Genprex, which operates within the competitive pharmaceutical industry under the ticker symbol (NASDAQ:GNPX). With a market capitalization of just $4.32 million and an overall Financial Health Score rated as WEAK by InvestingPro, the company faces significant hurdles ahead.
For deeper insights into Genprex’s financial health and 13 additional ProTips, investors can access comprehensive analysis through InvestingPro. The information is based on a press release statement from the company and market data.
In other recent news, Genprex, Inc. has made notable strides in its clinical trials and licensing agreements, while also facing a potential delisting from the Nasdaq Capital Market. T
he company has successfully completed the Phase 1 dose escalation part of its Acclaim-3 clinical trial for Reqorsa® Gene Therapy in combination with Tecentriq® for extensive stage small cell lung cancer (ES-SCLC), and is moving forward to Phase 2. Genprex also secured an exclusive license from the University of Michigan for a patented gene therapy technology, concerning the combination of Reqorsa® Gene Therapy with ALK-inhibitors for potential treatment of ALK-positive lung cancer.
However, the company received a notification from the Nasdaq Stock Market about a shortfall in the minimum stockholders’ equity requirement for continued listing. Genprex has until January 2025 to submit a plan to regain compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.